Craig-Hallum Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $62

Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc.

ETON

0.00

Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ: ETON) with a Buy and raises the price target from $40 to $62.